Ribo Secures Orphan Drug Status in Europe for RBD1016 Targeting Hepatitis Delta Virus Suzhou Ribo Life Science and Ribocure Pharmaceuticals have announced that the EMA granted RBD1016 orphan drug status for HDV infections, marking a breakthrough in treatment options.

Ribo Secures Orphan Drug Status in Europe for RBD1016 Targeting Hepatitis Delta Virus #None #Orphan_Drug #Ribo #HDV_Treatment